Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:ATRS Antares Pharma (ATRS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Antares Pharma Stock (NASDAQ:ATRS) 30 days 90 days 365 days Advanced Chart Ad Porter & CompanyWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Get Antares Pharma alerts:Sign Up Key Stats Today's Range$5.59▼$5.5950-Day Range$5.59▼$5.5952-Week Range$3.11▼$5.60Volume6 shsAverage Volume3.29 million shsMarket Capitalization$955.06 millionP/E Ratio23.29Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAntares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Receive ATRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antares Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address ATRS Stock News HeadlinesBest Healthcare Penny StocksSeptember 18, 2024 | benzinga.comAntares Vision SpA AVJanuary 24, 2024 | morningstar.comMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern border is a travesty, but the 'invasion' I've found will have 10 times greater effects on our economy, and ultimately our way of life.October 24, 2024 | The Freeport Society (Ad)Antares Vision Share Price (AV.MI)December 7, 2023 | lse.co.ukAprea Therapeutics’ Promising Clinical Data and Distinctive Drug Profile: An Analysis of Jason McCarthy’s Buy RatingOctober 19, 2023 | markets.businessinsider.comAntares Reaches New 52-Week High (AIS)September 3, 2023 | thestreet.comAntares Vision SpA (ANV)August 2, 2023 | investing.comCOP Syringes Market Competitive Situation By 2030April 27, 2023 | marketwatch.comSee More Headlines ATRS Stock Analysis - Frequently Asked Questions How were Antares Pharma's earnings last quarter? Antares Pharma, Inc. (NASDAQ:ATRS) posted its quarterly earnings results on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, hitting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to analysts' expectations of $48.52 million. Antares Pharma had a trailing twelve-month return on equity of 7.43% and a net margin of 21.90%. What other stocks do shareholders of Antares Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), NVIDIA (NVDA), Micron Technology (MU), Meta Platforms (META) and Prospect Capital (PSEC). Company Calendar Last Earnings11/04/2021Today10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:ATRS CUSIP03664210 CIK1016169 Webwww.antarespharma.com Phone(609) 359-3020Fax302-655-5049Employees201Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.24 Trailing P/E Ratio23.29 Forward P/E Ratio69.88 P/E GrowthN/ANet Income$46.29 million Net Margins21.90% Pretax Margin29.84% Return on Equity7.43% Return on Assets4.92% Debt Debt-to-Equity Ratio0.10 Current Ratio3.08 Quick Ratio2.87 Sales & Book Value Annual Sales$183.98 million Price / Sales5.19 Cash Flow$0.13 per share Price / Cash Flow43.89 Book Value$1.03 per share Price / Book5.43Miscellaneous Outstanding Shares170,852,000Free Float160,772,000Market Cap$955.06 million OptionableOptionable Beta1.15 Social Links 10 Best Stocks to Own in 2025Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ATRS) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Antares Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Antares Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.